Algenpantucel-L

Summary

Algenpantucel-L (CHEMBL2108717) is a phase-3 clinical-stage cell; indicated across 1 condition including exocrine pancreatic carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Cell
• Indications: 1 condition
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108717
Name	Algenpantucel-L
Type	Cell
Max phase	3

Also known as: Algenpantucel-l, HAPA, Hyperacute-pancreas immunotherapy, ALGENPANTUCEL-L

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
exocrine pancreatic carcinoma	3	MONDO:0005192	EFO:0002618

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01072981	PHASE3	COMPLETED	Immunotherapy Study for Surgically Resected Pancreatic Cancer
NCT01836432	PHASE3	TERMINATED	Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
NCT02405585	PHASE2	TERMINATED	Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
NCT06931106	Not specified	NOT_YET_RECRUITING	Behavioral Intervention for PrEP Service Utilization Among Chinese MSM: A HAPA and CEI Integrated Model

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).